Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Hesse

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
Journal of Clinical Medicine|June 28, 2023
Fibrous Dysplasia of the Jaw: Advances in Imaging and TreatmentKatharina Theresa Obermeier, Jens Tobias Hartung, Tim Hildebrandt, et al.
Cancer Research|January 31, 2015
Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone DiseaseHanna Taipaleenmäki, Gillian Browne, Jacqueline Akech, et al.
Acta Biomaterialia|April 5, 2016
Intramedullary Mg2Ag nails augment callus formation during fracture healing in miceKatharina Jähn, Hiroaki Saito, Hanna Taipaleenmäki, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 24, 2020
T-Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH TrialFelicia Cosman, E Michael Lewiecki, Peter R Ebeling, et al.
The Journal of Cell Biology|December 22, 2010
Zfp521 controls bone mass by HDAC3-dependent attenuation of Runx2 activityEric Hesse, Hiroaki Saito, Riku Kiviranta, et al.
Bone|December 20, 2008
Zfp521 antagonizes Runx2, delays osteoblast differentiation in vitro, and promotes bone formation in vivoMeilin Wu, Eric Hesse, Frederic Morvan, et al.
Bone|February 16, 2010
Repair of a segmental long bone defect in human by implantation of a novel multiple disc graftEric Hesse, Gerald Kluge, Azeddine Atfi, et al.
JBMR Plus|November 11, 2021
Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment GoalsFelicia Cosman, Cesar Libanati, Cynthia Deignan, et al.
EMBO Molecular Medicine|October 4, 2022
Antagonizing microRNA-19a/b augments PTH anabolic action and restores bone mass in osteoporosis in miceHanna Taipaleenmäki, Hiroaki Saito, Saskia Schröder, et al.
Disease Models & Mechanisms|February 10, 2021
Multiscale molecular profiling of pathological bone resolves sexually dimorphic control of extracellular matrix compositionAikta Sharma, Alice Goring, Peter B Johnson, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Journal of Clinical Medicine|June 28, 2023
Fibrous Dysplasia of the Jaw: Advances in Imaging and TreatmentKatharina Theresa Obermeier, Jens Tobias Hartung, Tim Hildebrandt, et al.
Cancer Research|January 31, 2015
Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone DiseaseHanna Taipaleenmäki, Gillian Browne, Jacqueline Akech, et al.
Acta Biomaterialia|April 5, 2016
Intramedullary Mg2Ag nails augment callus formation during fracture healing in miceKatharina Jähn, Hiroaki Saito, Hanna Taipaleenmäki, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 24, 2020
T-Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH TrialFelicia Cosman, E Michael Lewiecki, Peter R Ebeling, et al.
The Journal of Cell Biology|December 22, 2010
Zfp521 controls bone mass by HDAC3-dependent attenuation of Runx2 activityEric Hesse, Hiroaki Saito, Riku Kiviranta, et al.
Bone|December 20, 2008
Zfp521 antagonizes Runx2, delays osteoblast differentiation in vitro, and promotes bone formation in vivoMeilin Wu, Eric Hesse, Frederic Morvan, et al.
Bone|February 16, 2010
Repair of a segmental long bone defect in human by implantation of a novel multiple disc graftEric Hesse, Gerald Kluge, Azeddine Atfi, et al.
JBMR Plus|November 11, 2021
Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment GoalsFelicia Cosman, Cesar Libanati, Cynthia Deignan, et al.
EMBO Molecular Medicine|October 4, 2022
Antagonizing microRNA-19a/b augments PTH anabolic action and restores bone mass in osteoporosis in miceHanna Taipaleenmäki, Hiroaki Saito, Saskia Schröder, et al.
Disease Models & Mechanisms|February 10, 2021
Multiscale molecular profiling of pathological bone resolves sexually dimorphic control of extracellular matrix compositionAikta Sharma, Alice Goring, Peter B Johnson, et al.
Pageof 6